Finerenone Reduces Heart Failure Events and Cardiovascular Deaths: FINEARTS-HF trial
Recent research presented at ESC Congress 2024 reveals that finerenone decreased the incidence of heart failure events and cardiovascular deaths in patients with heart failure and either mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF).
The FINEARTS-HF trial was a double-blind, randomized study involving patients with heart failure (NYHA functional class II–IV) and a left ventricular ejection fraction (LVEF) of 40% or higher. Participants were also required to be 40 years of age or older, have elevated natriuretic peptide levels, and show signs of structural heart disease.
Eligible patients were randomly assigned to receive either finerenone (up to 40 mg daily, based on their initial estimated glomerular filtration rate [eGFR]) or a placebo.
The main goal of the study was to assess a combination of worsening heart failure events (both new and recurring) and cardiovascular death.
Secondary goals included overall mortality and a composite kidney outcome, which encompassed a sustained 50% or more drop in eGFR, a sustained decline in eGFR to below 15 ml/min/1.73 m², or the start of chronic dialysis or kidney transplantation.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.